Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.

@article{Tsimberidou2004PilotSO,
  title={Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.},
  author={Apostolia-Maria Tsimberidou and Francis J Giles and Madeleine Duvic and Razelle Kurzrock},
  journal={Journal of the American Academy of Dermatology},
  year={2004},
  volume={51 2},
  pages={200-4}
}
BACKGROUND Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL). OBJECTIVE To assess the toxicity, safety, and efficacy of etanercept (soluble TNF receptor) in patients with relapsed CTCL. METHODS Etanercept was administered twice weekly at a dose of 25 mg subcutaneously. Patients with improvement after two months could be continued on treatment. RESULTS Twelve out of the 13 patients enrolled on study were evaluable (Stage I-IIA, 3… CONTINUE READING